The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 18, 2023
Filed:
Jul. 19, 2017
Applicant:
F-star Beta Limited, Cambridge, GB;
Inventors:
Mihriban Tuna, Cambridge, GB;
Kin-Mei Leung, Cambridge, GB;
Haijun Sun, Cambridge, GB;
Melanie Medcalf, Cambridge, GB;
Samine Isaac, Cambridge, GB;
Assignee:
F-star Therapeutics Limited, Cambridge, GB;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/22 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 31/517 (2006.01); A61K 47/68 (2017.01); A61P 11/00 (2006.01); A61P 35/00 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 31/517 (2013.01); A61K 39/39558 (2013.01); A61K 47/6813 (2017.08); A61K 47/6845 (2017.08); A61P 11/00 (2018.01); A61P 35/00 (2018.01); C07K 16/22 (2013.01); C07K 16/2818 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2318/20 (2013.01);
Abstract
The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR). The specific binding members preferably comprise an EGFR antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members are expected to find application in the treatment of cancers expressing EGFR.